Spectrum Pharma (SPPI) Cash Flow Statement

Click line-items for a historical chart and %

Net income (loss)
Amortization of deferred revenue
Depreciation and amortization	19.49M
Stock-based compensation	9.75M
Change in fair value of common stock warrant liability
Provision for bad debt	-15K
Accounts receivable, net	-12.04M
Inventories, net	-6.77M
Prepaid expenses and other assets	804K
Accounts payable and other accrued obligations	-6.6M
Accrued compensation and related expenses	-451K
Accrued drug development costs	-526K
Landlord contributions to tenant improvements
Deferred revenue and other credits
Net cash provided by (used in) operating activities	-37.09M
Maturities of marketable securities
Purchases of marketable securities
Purchases of property and equipment	-61K
Net cash used in investing activities	-62K
Proceeds from issuance of common stock from stock option exercises	190K
Proceeds from contributions to ESPP
Repayment of capital leases
Net cash provided by financing activities	68.91M
Net increase (decrease) in cash and cash equivalents	31.86M
Cash and cash equivalents--beginning of period	139.74M
Cash and cash equivalents--end of period	171.61M
Conversion of preferred stock to common stock
Common stock issued for Targent milestone
Targent milestones included in intangible assets and accrued liabilities

Entities mentioned with SPPI

View All Entities